Jing-Ping Liou

查看斯高帕斯 (Scopus) 概要

電子郵件jpltmu.edutw

h-index

每年研究成果

學歷

2000 臺灣大學醫學院藥研所博士
1996 臺灣大學醫學院藥研所碩士
1994 臺北醫學院藥學系學士

經歷

2023.08- 臺北醫學大學研究發展處研發長
2021.11- 臺北醫學大學新藥開發研究中心主任
2017.06- 臺北醫學大學生技醫藥商品化中心主任
2018.01-2023.12 臺北醫學大學藥學院院長
2015.08-2022.07 臺北醫學大學藥學院生技製藥研究中心主任
2013.09-2017.12 臺北醫學大學藥學院副院長
2013.08- 臺北醫學大學中草藥臨床藥物研發博士學位學程
2013.08- 臺北醫學大學癌症生物學與藥物研發博士學位學程
2012.10-2016.12 臺北醫學大學藥物有機合成核心服務實驗室主任
2012.08- 臺北醫學大學藥物科學學科教授
2012.02-2012.07 臺北醫學大學藥物科學學科副教授
2008.02-2012.01 臺北醫學大學藥學系副教授
2004.10-2008.01 臺北醫學大學藥學系助理教授

獎項

2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University

1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion

研究興趣

抗癌小分子化合物設計與合成
有機合成

指紋

查看啟用 Jing-Ping Liou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

1 使用中
39 已完成

脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(3/3)
Liou, J.-P. (PI)
8/1/24 → 7/31/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
利用LSD1/HDAC雙效抑制劑治療去勢抗性前列腺癌
Liou, J.-P. (PI)
7/1/24 → 2/28/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
Microfluidic production of lipid- peptide nanoparticles for inhalable mRNA dry powder formulation
Liou, J.-P. (PI)
7/1/24 → 2/28/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(2/3)
Liou, J.-P. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
有機鈀金屬促進關鍵抗腫瘤片段的縫合以建構雙功能抗癌化學結構(3/3)
Liou, J.-P. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會

164 文章
21 回顧型文獻
8 評論/辯論
1 Erratum

Advancing glioblastoma therapy: Learning from the past and innovations for the future
Rana, M., Liou, K. C., Thakur, A., Nepali, K. & Liou, J. P., 5月 1 2025, 於: Cancer Letters. 617, 217601.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Design, preparation, and characterization of injectable thermosensitive polymer-based hydrogels with enhanced mechanical properties for sustained liraglutide release
Cheng, W. J., Yeh, T. Y., Hsieh, C. Y., Chuang, H. Y., Chao, F. C., Liou, J. P. & Hsieh, C. M., 6月 2025, 於: Journal of Drug Delivery Science and Technology. 108, 106909.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Development of BACE2-IN-1/tranylcypromine-based compounds to induce steroidogenesis-dependent neuroprotection
Banerjee, S., Hsu, Y. T., Nguyen, D. H., Yeh, S. H., Liou, K. C., Liu, J. J., Liou, J. P. & Chuang, J. Y., 2月 2025, 於: Biomedicine and Pharmacotherapy. 183, 117851.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies
Chen, I. C., Lin, H. Y., Liu, Z. Y., Cheng, W. J., Yeh, T. Y., Yang, W. B., Tran, H. Y., Lai, M. J., Wang, C. H., Kao, T. Y., Hung, C. Y., Huang, Y. L., Liou, K. C., Hsieh, C. M., Hsu, T. I. & Liou, J. P., 2025, 於: Journal of Medicinal Chemistry. 68, 3, p. 2779-2803 25 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., 7月 2024, 於: Cell Death and Disease. 15, 7, 490.
研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
資料集: Dataset
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
資料集: Dataset
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H.-J. (Contributor), Lin, Y.-J. (Contributor), Chao, M.-W. (Contributor), Sung, T.-Y. (Creator), Wu, Y.-W. (Creator), Chen, Y.-Y. (Creator), Lin, M.-H. (Contributor), Liou, J.-P. (Creator), Pan, S.-L. (Contributor) & Yang, C.-R. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
資料集: Dataset
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
資料集: Dataset
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset

劉景平

個人檔案

學歷

經歷

獎項

研究興趣

指紋

過去五年中的合作和熱門研究領域

深入探索詳細資料

脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(3/3)

利用LSD1/HDAC雙效抑制劑治療去勢抗性前列腺癌

Microfluidic production of lipid- peptide nanoparticles for inhalable mRNA dry powder formulation

脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(2/3)

有機鈀金屬促進關鍵抗腫瘤片段的縫合以建構雙功能抗癌化學結構(3/3)

Advancing glioblastoma therapy: Learning from the past and innovations for the future

Design, preparation, and characterization of injectable thermosensitive polymer-based hydrogels with enhanced mechanical properties for sustained liraglutide release

Development of BACE2-IN-1/tranylcypromine-based compounds to induce steroidogenesis-dependent neuroprotection

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies

Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells

Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

劉 景平

個人檔案

學歷

經歷

獎項

研究興趣

指紋

過去五年中的合作和熱門研究領域

專案

研究成果

資料集

劉景平